Page 12 of 15: studies 111 to 120 of 144, newest first. Back to the ketamine for addiction overview
March 1, 2020 Adam Winstock, James W. Rucker 29 citations
Abstract Psychedelics and hallucinogens represent some of the most commonly used drugs in the world, with a history of use steeped in spirituality, counter-culture, and more recently latent therapeutic potential. Sharing a common mechanism of action at the 5-HT2a receptor, drugs such as lysergic acid diethylamide (LSD) and psilocybin, while they can rarely induce significant short-term...
American Journal of Psychiatry December 2, 2019 Elias Dakwar, Frances R. Levin, C. Hart et al. 179 citations
OBJECTIVE Pharmacotherapy and behavioral treatments for alcohol use disorder are limited in their effectiveness, and new treatments with innovative mechanisms would be valuable. In this pilot study, the authors tested whether a single subanesthetic infusion of ketamine administered to adults with alcohol dependence and engaged in motivational enhancement therapy affects drinking outcomes....
Behavioural Brain Research September 2, 2019 M L Shawn Bates, Keith A Trujillo
Initiation of ketamine use often occurs in adolescence, yet little is known about long-term consequences when use begins in this developmental period. The current experiments were designed to examine the effects of repeated exposure to ketamine in adolescence on behavior in adulthood. We examined locomotor activity, as well as cognitive function, in animals that received repeated administration...
American Journal of Psychiatry June 24, 2019 Elias Dakwar, E. Nunes, C. Hart et al. 179 citations
OBJECTIVE Research has suggested that subanesthetic doses of ketamine may work to improve cocaine-related vulnerabilities and facilitate efforts at behavioral modification. The purpose of this trial was to test whether a single ketamine infusion improved treatment outcomes in cocaine-dependent adults engaged in mindfulness-based relapse prevention. METHODS Fifty-five cocaine-dependent...
JAMA Psychiatry March 1, 2019 Gihyun Yoon, Ismene L. Petrakis, John H. Krystal 152 citations
This study examines whether naltrexone pretreatment interferes with the antidepressant effects of ketamine.
Chronic Stress 2019 Katherine N Wright, Devin P Hagarty, C. Strong et al.
Background Ketamine has rapid antidepressant effects and shows great promise as a novel treatment for depression, but its limitations including its abuse potential are poorly understood. Given that the prevalence of depression is twice as high in women as in men and that depression and substance use disorders are highly comorbid, we hypothesized that a sex-specific responsivity to behavioral...
Biologie aujourd'hui 2019 Rémi Corne, Raymond Mongeau 7 citations
Psychedelic drugs, often referred to as hallucinogens, are quite distinct from other classes of psychotropic drugs. Although the subjective and behavioral effects they induce are quite dramatic, they possess little addictive potential when compared to nicotine, alcohol or opiates. Since the discovery of ketamine antidepressant effects, there has been growing interest for these molecules....
Neuropharmacology November 2018 I Ivan Ezquerra-Romano, W Lawn, E Krupitsky et al.
Ketamine is a dissociative anaesthetic drug which acts on the central nervous system chiefly through antagonism of the n-methyl-d-aspartate (NMDA) receptor. Recently, ketamine has attracted attention as a rapid-acting anti-depressant but other studies have also reported its efficacy in reducing problematic alcohol and drug use. This review explores the preclinical and clinical research into...
Neuropharmacology November 1, 2018 Elias Dakwar, Edward V. Nunes, Carl L. Hart et al. 83 citations
Efforts to translate sub-anesthetic ketamine infusions into widespread clinical use have centered around developing medications with comparable neurobiological activity, but with attenuated psychoactive effects so as to minimize the risk of behavioral toxicity and abuse liability. Converging lines of research, however, suggest that some of the psychoactive effects of sub-anesthetic ketamine may...
International Journal of Environmental Research and Public Health April 17, 2018 Carola Rong, Caroline Park, Joshua D. Rosenblat et al. 116 citations
OBJECTIVES: Extant evidence indicates that ketamine exerts rapid antidepressant effects in treatment-resistant depressive (TRD) symptoms as a part of major depressive disorder (MDD) and bipolar disorder (BD). The identification of depressed sub-populations that are more likely to benefit from ketamine treatment remains a priority. In keeping with this view, the present narrative review aims to...